Detection of metastatic disease in patients with uveal melanoma using positron emission tomography

European Journal of Surgical Oncology

Volumn 32, Issue 7, 2006, Pages 780-784

  Francken, A B ^a   Fulham, M J ^b   Millward, M J ^a,b   Thompson, J F ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Liver; Metastasis; Positron emission tomography; Uveal melanoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AUSTRALIA; CALCULATION; CANCER REGISTRY; CANCER SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIODIAGNOSIS; SENSITIVITY AND SENSIBILITY; UVEA MELANOMA;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; UVEAL NEOPLASMS;

EID: 33747791209     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2006.04.011     Document Type: Article

References (25)

1. Vajdic C.M., Kricker A., Giblin M., et al. Incidence of ocular melanoma in Australia from 1990 to 1998. Int J Cancer 105 1 (2003) 117-122
2. Damato B. Developments in the management of uveal melanoma. Clin Exp Ophthalmol 32 6 (2004) 639-647
3. Albert D.M., Ryan L.M., and Borden E.C. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 114 1 (1996) 107-108
4. Donoso L.A., Berd D., Augsburger J.J., Mastrangelo M.J., and Shields J.A. Metastatic uveal melanoma. Pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol 103 6 (1985) 796-798
5. McCarthy W.H., Shaw H.M., Thompson J.F., and Milton G.W. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 166 6 (1988) 497-502
6. Rajpal S., Moore R., and Karakousis C.P. Survival in metastatic ocular melanoma. Cancer 52 2 (1983) 334-336
7. Mooy C.M. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41 3 (1995) 215-228
8. Hsueh E.C., Essner R., Foshag L.J., Ye X., Wang H.J., and Morton D.L. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer 100 1 (2004) 122-129
9. Damian D.L., Fulham M.J., Thompson E., and Thompson J.F. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 6 4 (1996) 325-329
10. Holder Jr. W.D., White Jr. R.L., Zuger J.H., Easton Jr. E.J., and Greene F.L. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227 5 (1998) 764-769
11. Prichard R.S., Hill A.D., Skehan S.J., and O'Higgins N.J. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 89 4 (2002) 389-396
12. Diener-West M. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol 22 12 (2004) 2438-2444
13. Alexander Jr. H.R., Libutti S.K., Pingpank J.F., et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 9 17 (2003) 6343-6349
14. Allen P.J., and Coit D.G. The role of surgery for patients with metastatic melanoma. Curr Opin Oncol 14 2 (2002) 221-226
15. Carroll N.M., and Alexander Jr. H.R. Isolation perfusion of the liver. Cancer J 8 2 (2002) 181-193
16. Libutti S.K., Barlett D.L., Fraker D.L., and Alexander H.R. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg 191 5 (2000) 519-530
17. Rose D.M., Essner R., Hughes T.M., et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 136 8 (2001) 950-955
18. Wood T.F., DiFronzo L.A., Rose D.M., et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival?. Ann Surg Oncol 8 8 (2001) 658-662
19. Meikle S.R. Simultaneous emission and transmission measurements for attenuation correction in whole-body PET. J Nucl Med 36 9 (1995) 1680-1688
20. Finger P.T., Kurli M., Reddy S., Tena L.B., and Pavlick A.C. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 89 10 (2005) 1270-1274
21. Freudenberg L.S. Whole-body fluorine-18 fluordeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in staging of advanced uveal melanoma. Surv Ophthalmol 49 5 (2004) 537-540
22. Kurli M., Reddy S., Tena L.B., Pavlick A.C., and Finger P.T. Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol 140 2 (2005) 193-199
23. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 119 5 (2001) 670-676
24. Rinne D., Baum R.P., Hor G., and Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 82 9 (1998) 1664-1671
25. Peterson J.J., Kransdorf M.J., and O'Connor M.I. Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop 415 Suppl. (2003) S120-S128